Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroups
Leone A, Mai A, Fong K, Yap D, Kato K, Smyth E, Moehler M, Seong J, Sundar R, Zhao J, Pietrantonio F. Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroups. ESMO Open 2024, 9: 103962. PMID: 39426081, PMCID: PMC11533044, DOI: 10.1016/j.esmoop.2024.103962.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsCombined positive scoreBenefit of immune checkpoint inhibitorsCheckpoint inhibitorsOS benefitOverall survivalAnti-programmed cell death protein 1Kaplan-Meier (KM) plotsEfficacy of immune checkpoint inhibitorsFirst-line immune checkpoint inhibitorsPD-L1 combined positive scoreProgrammed death ligand 1 subgroupsCell death protein 1Programmed death-ligand 1Patient-level meta-analysesPatient-level meta-analysisDeath-ligand 1Advanced gastroesophageal adenocarcinomaRandomized clinical trialsCheckMate-649KEYNOTE-062Gastroesophageal adenocarcinomaTherapeutic optionsClinical trialsKM plots